{"id":"W2135530224","doi":"10.1200/jco.2014.57.1513","title":"Primary Results of ROSE/TRIO-12, a Randomized Placebo-Controlled Phase III Trial Evaluating the Addition of Ramucirumab to First-Line Docetaxel Chemotherapy in Metastatic Breast Cancer","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":135,"is_retracted":false,"has_abstract":true,"ca_institutions":"BC Cancer Agency","funders":"Eli Lilly and Company","keywords":"Ramucirumab; Docetaxel; Medicine; Metastatic breast cancer; Internal medicine; Oncology; Hazard ratio; Clinical endpoint; Taxane; Breast cancer; Placebo; Chemotherapy; Progression-free survival; Cancer; Randomized controlled trial; Pathology; Confidence interval","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003655808,0.002324747,0.003815761,0.0004702456,0.0005237994,0.001231555,0.001207182,0.001754329,0.01256345],"category_scores_gemma":[0.003149331,0.0006877119,0.001902045,0.000395415,0.001506093,0.0009920312,0.00030942,0.004375522,0.002164301],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007878494,"about_ca_system_score_gemma":0.001643452,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005488636,"about_ca_topic_score_gemma":0.00145274,"domain_scores_codex":[0.9987999,0.0006981143,0.0000749915,0.0002048313,0.0001107984,0.0001113135],"domain_scores_gemma":[0.998473,0.0003877147,0.0004306791,0.0001190799,0.0001276036,0.0004619798],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9668617,0.006448132,0.0005898551,0.001341898,0.0009733947,0.00005061237,0.00003783717,0.0002963687,0.003407339,0.0001732946,0.003035831,0.01678381],"study_design_scores_gemma":[0.9565931,0.03917356,0.001249287,0.0000565954,0.0006238489,0.00004878456,0.000005653387,0.0001628725,0.0008419366,0.0001023906,0.001132411,0.00000955861],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9141552,0.02837454,0.001879894,0.002902785,0.001425191,0.02162655,0.0108927,0.0007868013,0.0179564],"genre_scores_gemma":[0.9563463,0.00859712,0.004311334,0.002954432,0.001165143,0.01156464,0.006506432,0.0001128337,0.008441722],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01256345,"threshold_uncertainty_score":0.0420289,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1991386133547665,"score_gpt":0.5626661216359241,"score_spread":0.3635275082811576,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}